Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and lederle whole-cell component DTP vaccine in german children after household exposure

Pediatrics

Volumn 102, Issue 3 I, 1998, Pages 546-553

  Heininger, Ulrich ^a   Cherry, James D ^b   Stehr, Klemens ^a   Schmitt Grohé, Sabina ^a   Überall, Michael ^a   Laussucq, Suzanne ^c   Eckhardt, Thomas ^c   Meyer, Martin ^d   Gornbein, Jeffrey ^e  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acellular pertussis vaccine; Bordetella pertussis; Household contact; Vaccine efficacy; Whole cell pertussis vaccine

Indexed keywords

COTRIMOXAZOLE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MACROLIDE; PERTUSSIS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BORDETELLA PERTUSSIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION CONTROL; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL;

DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; ENVIRONMENTAL EXPOSURE; FEMALE; GERMANY; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WHOOPING COUGH;

EID: 0031657944     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.102.3.546     Document Type: Article

References (34)

1. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 1998;101:1-11
2. Gordon JE, Hood RI. Whooping cough and its epidemiological anomalies. Am J Med Sci. 1951;222:333-361
3. Kendrick PL. Secondary familial attack rates from pertussis in vaccinated and unvaccinated children. Am J Hyg. 1940;32:89-91
4. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis. 1987;9:866-883
5. Fine PEM, Clarkson JA, Miller E. The efficacy of pertussis vaccines under conditions of household exposure. Further analysis of the 1978-80 PHLS/ERL study in 21 area health authorities in England. Int J Epidemiol. 1988;17:635-642
6. Onorato I, Wassilak S, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA. 1992;267:2745-2749
7. Heininger U, Cherry JD, Eckhardt T, Lorenz C, Christenson P, Stehr K. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr Infect Dis J. 1993;12:504-509
8. Schläpfer G, Cherry JD, Heininger U, et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis J. 1995;14:209-214
9. Manclark CR, Meade BD, Burstyn DG. Serologic response to Bordetella pertussis. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:388-394
10. Blumberg DA, Mink CM, Cherry JD, et al. Comparison of an acellular pertussis-component diphtheria-tetanus-perrussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. J Pediatr. 1990;117:46-51
11. Blumberg DA, Mink CM, Cherry JD, et al. Comparison of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. J Pediatr. 1991;119:194-204
12. Heininger U, Cherry JD, Christenson P, et al. Comparative study of Lederle/Takeda acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine. 1994;12: 81-86
13. Orenstein WA, Bernier RH, Dondero T, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63:1055-1068
14. Fine PEM. Implications of different study designs for the evaluation of acellular pertussis vaccines. Dev Biol Stand. 1997;89:866-883
15. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275:37-41
16. Storsaeter J, Blackwelder WC, Hallander HO. Pertussis antibodies, protection, and vaccine efficacy after household exposure. Am J Dis Child. 1992;146:167-172
17. Trollfors B, Taranger J, Lagergard T, et al. Efficacy of a monocomponent pertussis-toxoid vaccine after household exposure to pertussis. J Pediatr. 1997;130:532-536
18. Wirsing von König CH, Schmitt HJ, Bogaerts H, et al. Factors influencing the analysis of secondary prevention of pertussis. Dev Biol Stand. 1997;89:175-179
19. Mortimer EA, Kimura M, Cherry JD, et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child. 1990;144:899-904
20. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. In press
21. Simondon F, Preziosi M, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997;15:1606-1612
22. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med. 1995;333:1045-1050
23. Gustafsson L, Hallander H, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334:349-355
24. Deen J, Mink CM, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis. 1995;21:1211-1219
25. Bass JW. Erythromycin for treatment and prevention of pertussis. Pediatr Infect Dis. 1986;5:154-157
26. Sprauer MA, Cochi SL, Zell ER, et al. Prevention of secondary transmission of pertussis in households with early use of erythromycin. AJDC. 1992;146:177-181
27. Steketee RW, Wassilak SGF, Adkins WN, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis. 1988;157:434-440
28. Biellik RJ, Patriarca PA, Mullen JR, et al. Risk factors for community-and household-acquired pertussis during a large-scale outbreak in central Wisconsin. J Infect Dis. 1988;157:1134-1141
29. De Serres G, Boullianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J. 1995;14:969-975
30. Wirsing von König CH, Schmitt HJ, Bogaerts H, et al. Factors influencing the analysis of secondary prevention of pertussis. Dev Biol Stand. 1997;89:175-179
31. Heininger U, Klich K, Stehr K, Cherry JD. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics. 1997;100(6). URL: http:www.pediatrics.org/cgi/ content/full/100/6/e10
32. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334:341-348
33. Cherry JD, Heininger U, Stehr K, Engelhardt R, Christenson P. The effect of observer bias in pertussis vaccine efficacy trials. Pediatr Res. 1997;41:75A
34. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J. 1997;16:S90-S96